Posted by Michael Wonder on 01 Feb 2023
ABPI response to new MHRA fees announced for 1 April 2023
1 February 2023 - These fee increases are an important step to ensuring the MHRA has the resources it needs to deliver the high-quality service that the public expects and industry needs.
The decision not to implement new fees for ILAP and complex amendments to clinical trials is the right one, and we look forward to working with the MHRA to ensure their future fee charging mechanism remains fit for purpose.
